Jarvik Heart

Executive Summary

Jarvik Heart, founded in 1988 in New York, is a private medical device company specializing in cardiovascular solutions, particularly continuous-flow left ventricular assist devices (LVADs). The company pioneered wireless coplanar energy transfer technology for heart pumps, as demonstrated in a 2019 first-in-human study published in The Journal of Heart and Lung Transplantation. This innovation allows for transcutaneous energy transmission, eliminating the need for drivelines that can cause infections. Jarvik Heart's technology has been implanted in patients in Kazakhstan, indicating early clinical adoption. Despite limited recent public updates, the company's longstanding expertise and unique wireless charging capability position it as a potential leader in the LVAD market, which is growing due to increasing heart failure prevalence. However, competition from larger players like Abbott and Medtronic, and the need for regulatory approvals, present challenges. The company's stage and financing details remain undisclosed, suggesting a private, possibly venture-backed, trajectory.

Upcoming Catalysts (preview)

• TBDFDA Approval for Wireless LVAD System40% success
• TBDPublication of Long-Term Clinical Data50% success
• TBDStrategic Partnership or Acquisition by Major MedTech Firm30% success